Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of
SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A
who have been previously treated with coagulation factor VIII(FVIII) . This study includes
two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of
SCT800 shall be administered once every other day or three times per week starting from V1,
on-demand treatment is given when bleeding episodes occur. The study period is 120
consecutive weeks.